Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development

Advertisement

Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development

  • Dan Raffi appointed Director of Commercial Operations
  • Raoul Bernhardt appointed Director of Industrial Operations

Villepinte, 10 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments. Dan Raffi and Raoul Bernhardt have joined the Group as Director of Commercial Operations and Director of Industrial Operations respectively. They will both become members of Guerbet’s Executive Committee


Dan RAFFI – Director of Commercial Operations

Advertisement

Raoul Bernhardt – Director of Industrial Operations

Guerbet’s Executive Committee now has 9 members:

  • David Hale, Chief Executive Officer
  • Charlotte Bamière, Director of Legal Affairs
  • Raoul Bernhardt, Director of Industrial Operations
  • Philippe Bourrinet, Director of Development, Medical & Regulatory Affairs, and Group Chief Pharmacist
  • Valérie Brissart, Director of Diagnostic Imaging
  • Jérôme Estampes, Chief Financial Officer and Senior VP Business Development and Licensing
  • Leïla Mechaï, Director of Human Resources and Corporate Social Responsibility
  • François Nicolas, Director of R&D, R&I and Chief Digital Officer
  • Dan Raffi, Director of Commercial Operations

Upcoming events:

Publication of first-half annual revenue
20 July 2023 after trading

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 95 years, with more than 2,830 employees worldwide, we are constantly innovating and devote 8% to 10% of our revenue to research and development in five centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022. For more information, please visit www.guerbet.com.

Attachment

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.